GLOBAL CELL THERAPY MARKET FORECAST 2022-2030

The global cell therapy market is expected to reach $6718.98 million by 2030, growing at a CAGR of 14.46% during the forecast period, 2022-2030. The base year considered for the study is 2021, and the estimated period is between 2022 and 2030. The market study has also analyzed the impact of COVID-19 on the cell therapy market qualitatively as well as quantitatively.

GLOBAL CELL THERAPY MARKET FORECAST 2022-2030

Global Cell Therapy Market by Cell Type (Stem Cell (Bone Marrow, Blood, Umbilical Cord-derived Stem Cell, Adipose-derived Stem Cell, Others), Non-stem Cell) Market by Therapy Type (Autologous, Allogeneic) Market by Therapeutic Application (Malignancies, Musculoskeletal Disorders, Autoimmune Disorders, Dermatology, Other Applications) Market by End-user (Hospitals & Clinics, Academic & Research Institutes) By Geography

Request free sample

Report Summary

Cell therapy is the transplantation of complete, living cells into a patient to help treat or cure an illness. The cells may come from the patient (autologous cells) or a donor (allogeneic cells). More than 8000 clinical studies for cell treatments are being researched for various illnesses, according to ClinicalTrials.gov. Blood transfusion, especially the transfusion of red blood cells, white blood cells, and platelets from a donor, is the most common type of cell therapy. The transplantation of hematopoietic stem cells to produce bone marrow, which has been done for more than 40 years, is another popular cell treatment.

Cell Therapy Market

Read our latest blog on the Cell Therapy Market

Key enablers of the global cell therapy market growth are:

Increasing cellular therapy clinical trials
- Cell therapies have significant potential in treating damaged cells, tissues, and organs, including their repair, replacement, restoration, and regeneration. Cell-based therapies that are both efficient and secure are currently being developed by researchers. The number of current clinical studies in various stages of clinical trials has increased due to the presence of government and private financing organizations.
- According to the Cancer Research Institute (CRI), there are 2,073 active agents in the worldwide cellular therapy pipeline, 572 more than in 2020. In addition, 1,358 cell therapy trials are currently in progress, a 78% increase over the 762 active cell therapy trials reported in 2019 and a 43% rise between 2020 and 2021.
Growing number of regenerative medicines
High prevalence of chronic diseases

Key growth restraining factors are:

Increasing skills gap
- Cell therapy is a rapidly evolving experimental space. Several proof-of-concept medicines have received global regulatory clearance and commercial access. As a result, investments in cell therapies are expanding quickly. By 2025, the US Food and Drug Administration (FDA) expects to have approved 10 to 20 cell and gene therapies annually.
- However, the manufacturing, and particularly research & development of these novel therapies, is complex and labor-intensive. While increasing investments have helped the cell therapy industry advance, its fast-paced growth has resulted in a skills gap impeding patient access to much-needed medicines. Since a limited number of people have acquired the skills required to manufacture these emerging therapies, such individuals are in great demand.
High costs

Cell Therapy Market | Top Trends

In terms of innovation, the cell therapy pipeline in the pharmaceutical industry continues to be led by small biopharma companies.
Many companies and organizations are collaborating to develop stem cell therapies and regenerative medicines.
The companies are adopting fully automated cell therapy manufacturing processes as they might considerably reduce manual intervention and human error, enabling reliable operations, enhancing product quality, accelerating product delivery, and lowering costs.

To know more about this report, request a free sample copy

Market Segmentation Analysis – Cell Type, Therapy Type, Therapeutic Application, and End-User –

Market by Therapy Type:

Autologous
- Autologous is anticipated to be the fastest-growing therapy type in the market, with a CAGR of 15.66%. Autologous cell therapy is a cutting-edge therapeutic approach that utilizes a donor’s cells after being expanded and cultivated outside their body.
- The benefits of this therapy include lessened risks from systemic immunological responses, bio-incompatibility, and disease transmission associated with grafts or cells not cultured from the person. Autologous therapies are tailor-made products for each patient.
- This therapy has been effectively utilized to bioengineer skin replacements, aid in wound healing, reduce chronic inflammation, treat burns and pressure ulcers, and enhance postoperative recovery.
- Plus Therapeutics Inc is one of the companies that offer autologous cell therapies.
Allogeneic

Market by Therapeutic Application:

Malignancies
Musculoskeletal Disorders
Autoimmune Disorders
Dermatology
Other Applications

Market by Cell Type:

Stem Cell
- Bone Marrow
- Blood
- Umbilical Cord-Derived Stem Cell
- Adipose-Derived Stem Cell
- Others
Non-Stem Cell

Market by End-User:

Hospitals & Clinics
- Hospitals & clinics are the fastest-growing end-user in the global cell therapy market. Hospitals are increasing stem cell transplantation facilities by investing in infrastructure development. Many doctors claim stem cells have cured patients of health conditions such as knee pain, erectile dysfunction, asthma, congestive heart failure, and stroke.
- Furthermore, clinics offer stem cell treatments for neurological diseases, lung conditions, immunological conditions, paralysis, cerebral palsy, or autism. Also, the number of clinics is anticipated to increase globally as clinical trials continue to rise.
- In addition, there is increased government financing for hospitals & clinics and hospital involvement in stem cell treatment research. Besides, the proliferation of pipeline developments over the past few years contributes to the segment’s growth.
Academic & Research Institutes

Geographical Study based on Four Major Regions:

North America: The United States & Canada
- North America is anticipated to be the largest regional market for cell therapy, with a share of 51.45% in 2021. Also, the region is home to companies such as Gilead Sciences Inc, Bristol Myers Squibb Company, Vericel Corporation, NuVasive Inc, Kolon TissueGene, and Stemedica Cell Technologies Inc.
- Further, the robust regulatory framework and increased investments in clinical therapy trials promote the growth of the cell therapy market in North America. Additionally, the strong presence of research institutes and the increasing government funding contribute to market growth.
Europe: The United Kingdom, Germany, France, Italy, Spain, Belgium, Poland, and Rest of Europe
Asia-Pacific: China, Japan, India, South Korea, Thailand, Singapore, Australia & New Zealand, and Rest of Asia-Pacific
Rest of World: Latin America, Middle East & Africa

The major players in the global cell therapy market are:

Bristol Myers Squibb Company
Gilead Sciences Inc
Vericel Corporation
Smith & Nephew Plc
NuVasive Inc
MEDIPOST Co Ltd

Key strategies adopted by some of these companies:

Bristol Myers Squibb got clearance for Abecma (idecabtagene vicleucel) in January 2022, making it the first CAR T-cell therapy licensed in Japan to treat multiple myeloma.

The European Commission (EC) authorized Tecartus (brexucabtagene autoleucel), a CAR T-cell therapy from Kite, to treat B-cell precursor acute lymphoblastic leukemia in September 2022.

Sysmex Corporation and JCR Pharmaceuticals Co Ltd formed a joint venture in October 2022 for the research, development, production, and commercialization of cell-based regenerative medicine products such as hematopoietic stem cells and other stem cells.

Report Synopsis:

Report Scope	Details
Market Forecast Years	2022-2030
Base Year	2021
Market Historical Years	2018-2021
Forecast Units	Revenue ($ Million)
Segments Analyzed	Cell Type, Therapy Type, Therapeutic Application, and End-User
Geographies Analyzed	North America, Europe, Asia-Pacific, and Rest of World
Companies Analyzed	Anterogen Co Ltd, Bristol Myers Squibb Company, Cells for Cells SA, Gilead Sciences Inc, JCR Pharmaceuticals Co Ltd, Kolon TissueGene Inc, MEDIPOST Co Ltd, Mesoblast Limited, NuVasive Inc, Smith & Nephew Plc, Stemedica Cell Technologies Inc, Vericel Corporation

RESEARCH SCOPE & METHODOLOGY
- STUDY OBJECTIVES
- SCOPE OF STUDY
- METHODOLOGY
- ASSUMPTIONS & LIMITATIONS
EXECUTIVE SUMMARY
- MARKET SIZE & ESTIMATES
- MARKET OVERVIEW
MARKET DYNAMICS
- KEY DRIVERS
  - INCREASING CELLULAR THERAPY CLINICAL TRIALS
  - GROWTH OF REGENERATIVE MEDICINE
  - HIGH PREVALENCE OF CHRONIC DISEASES
- KEY RESTRAINTS
  - INCREASING SKILLS GAP
  - HIGH COSTS

KEY ANALYTICS
- IMPACT OF COVID-19 ON CELL THERAPY MARKET
- KEY MARKET TRENDS
- PORTER’S FIVE FORCES ANALYSIS
  - BUYERS POWER
  - SUPPLIERS POWER
  - SUBSTITUTION
  - NEW ENTRANTS
  - INDUSTRY RIVALRY
- REGULATORY FRAMEWORK
- OPPORTUNITY MATRIX
- VENDOR LANDSCAPE
MARKET BY CELL TYPE
- STEM CELL
  - BONE MARROW
  - BLOOD
  - UMBILICAL CORD-DERIVED STEM CELL
  - ADIPOSE-DERIVED STEM CELL
  - OTHERS
- NON-STEM CELL
MARKET BY THERAPY TYPE
- AUTOLOGOUS
- ALLOGENEIC
MARKET BY THERAPEUTIC APPLICATION
- MALIGNANCIES
- MUSCULOSKELETAL DISORDERS
- AUTOIMMUNE DISORDERS
- DERMATOLOGY
- OTHER APPLICATIONS
MARKET BY END-USER
- HOSPITALS & CLINICS
- ACADEMIC & RESEARCH INSTITUTES
GEOGRAPHICAL ANALYSIS
- NORTH AMERICA
  - MARKET SIZE & ESTIMATES
  - KEY DRIVERS
  - KEY CHALLENGES
  - KEY PLAYERS
  - COUNTRY ANALYSIS
    - UNITED STATES
    - CANADA
- EUROPE
  - MARKET SIZE & ESTIMATES
  - KEY DRIVERS
  - KEY CHALLENGES
  - KEY PLAYERS
  - COUNTRY ANALYSIS
    - UNITED KINGDOM
    - GERMANY
    - FRANCE
    - ITALY
    - SPAIN
    - BELGIUM
    - POLAND
    - REST OF EUROPE
- ASIA-PACIFIC
  - MARKET SIZE & ESTIMATES
  - KEY DRIVERS
  - KEY CHALLENGES
  - KEY PLAYERS
  - COUNTRY ANALYSIS
    - CHINA
    - JAPAN
    - INDIA
    - SOUTH KOREA
    - THAILAND
    - SINGAPORE
    - AUSTRALIA & NEW ZEALAND
    - REST OF ASIA-PACIFIC
- REST OF WORLD
  - MARKET SIZE & ESTIMATES
  - KEY DRIVERS
  - KEY CHALLENGES
  - KEY PLAYERS
  - REGIONAL ANALYSIS
    - LATIN AMERICA
    - MIDDLE EAST & AFRICA

COMPETITIVE LANDSCAPE
- KEY STRATEGIC DEVELOPMENTS
  - MERGERS & ACQUISITIONS
  - PRODUCT LAUNCHES & DEVELOPMENTS
  - PARTNERSHIPS & AGREEMENTS
  - BUSINESS EXPANSIONS
- COMPANY PROFILES
  - ANTEROGEN CO LTD
  - BRISTOL MYERS SQUIBB COMPANY
  - CELLS FOR CELLS SA
  - GILEAD SCIENCES INC
  - JCR PHARMACEUTICALS CO LTD
  - KOLON TISSUEGENE INC
  - MEDIPOST CO LTD
  - MESOBLAST LIMITED
  - NUVASIVE INC
  - SMITH & NEPHEW PLC
  - STEMEDICA CELL TECHNOLOGIES INC
  - VERICEL CORPORATION

LIST OF TABLES

TABLE 1: MARKET SNAPSHOT – CELL THERAPY

TABLE 2: REGULATORY FRAMEWORK

TABLE 3: GLOBAL CELL THERAPY MARKET, BY CELL TYPE, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 4: GLOBAL CELL THERAPY MARKET, BY CELL TYPE, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 5: GLOBAL STEM CELL MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 6: GLOBAL STEM CELL MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 7: GLOBAL CELL THERAPY MARKET, BY STEM CELL, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 8: GLOBAL CELL THERAPY MARKET, BY STEM CELL, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 9: GLOBAL BONE MARROW MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 10: GLOBAL BONE MARROW MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 11: GLOBAL BLOOD MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 12: GLOBAL BLOOD MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 13: GLOBAL UMBILICAL CORD-DERIVED STEM CELL MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 14: GLOBAL UMBILICAL CORD-DERIVED STEM CELL MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 15: GLOBAL ADIPOSE-DERIVED STEM CELL MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 16: GLOBAL ADIPOSE-DERIVED STEM CELL MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 17: GLOBAL OTHERS MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 18: GLOBAL OTHERS MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 19: GLOBAL NON-STEM CELL MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 20: GLOBAL NON-STEM CELL MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 21: GLOBAL CELL THERAPY MARKET, BY THERAPY TYPE, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 22: GLOBAL CELL THERAPY MARKET, BY THERAPY TYPE, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 23: GLOBAL AUTOLOGOUS MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 24: GLOBAL AUTOLOGOUS MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 25: GLOBAL ALLOGENEIC MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 26: GLOBAL ALLOGENEIC MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 27: GLOBAL CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 28: GLOBAL CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 29: GLOBAL MALIGNANCIES MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 30: GLOBAL MALIGNANCIES MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 31: GLOBAL MUSCULOSKELETAL DISORDERS MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 32: GLOBAL MUSCULOSKELETAL DISORDERS MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 33: GLOBAL AUTOIMMUNE DISORDERS MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 34: GLOBAL AUTOIMMUNE DISORDERS MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 35: GLOBAL DERMATOLOGY MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 36: GLOBAL DERMATOLOGY MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 37: GLOBAL OTHER APPLICATIONS MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 38: GLOBAL OTHER APPLICATIONS MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 39: GLOBAL CELL THERAPY MARKET, BY END-USER, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 40: GLOBAL CELL THERAPY MARKET, BY END-USER, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 41: GLOBAL HOSPITALS & CLINICS MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 42: GLOBAL HOSPITALS & CLINICS MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 43: GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 44: GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 45: GLOBAL CELL THERAPY MARKET, BY GEOGRAPHY, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 46: GLOBAL CELL THERAPY MARKET, BY GEOGRAPHY, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 47: NORTH AMERICA CELL THERAPY MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 48: NORTH AMERICA CELL THERAPY MARKET, BY COUNTRY, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 49: KEY PLAYERS IN NORTH AMERICA CELL THERAPY MARKET

TABLE 50: LIST FDA-APPROVED CELL THERAPY PRODUCTS

TABLE 51: EUROPE CELL THERAPY MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 52: EUROPE CELL THERAPY MARKET, BY COUNTRY, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 53: KEY PLAYERS IN EUROPE CELL THERAPY MARKET

TABLE 54: ASIA-PACIFIC CELL THERAPY MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 55: ASIA-PACIFIC CELL THERAPY MARKET, BY COUNTRY, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 56: KEY PLAYERS IN ASIA-PACIFIC CELL THERAPY MARKET

TABLE 57: REST OF WORLD CELL THERAPY MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 58: REST OF WORLD CELL THERAPY MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 59: KEY PLAYERS IN REST OF WORLD CELL THERAPY MARKET

TABLE 60: LIST OF MERGERS & ACQUISITIONS

TABLE 61: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS

TABLE 62: LIST OF PARTNERSHIPS & AGREEMENTS

TABLE 63: LIST OF BUSINESS EXPANSIONS

LIST OF FIGURES

FIGURE 1: KEY MARKET TRENDS

FIGURE 2: PORTER’S FIVE FORCES ANALYSIS

FIGURE 3: OPPORTUNITY MATRIX

FIGURE 4: VENDOR LANDSCAPE

FIGURE 5: GLOBAL CELL THERAPY MARKET, GROWTH POTENTIAL, BY CELL TYPE, IN 2021

FIGURE 6: GLOBAL CELL THERAPY MARKET, BY STEM CELL, 2022-2030 (IN $ MILLION)

FIGURE 7: GLOBAL CELL THERAPY MARKET, GROWTH POTENTIAL, BY STEM CELL, IN 2021

FIGURE 8: GLOBAL CELL THERAPY MARKET, BY BONE MARROW, 2022-2030 (IN $ MILLION)

FIGURE 9: GLOBAL CELL THERAPY MARKET, BY BLOOD, 2022-2030 (IN $ MILLION)

FIGURE 10: GLOBAL CELL THERAPY MARKET, BY UMBILICAL CORD-DERIVED STEM CELL, 2022-2030 (IN $ MILLION)

FIGURE 11: GLOBAL CELL THERAPY MARKET, BY ADIPOSE-DERIVED STEM CELL, 2022-2030 (IN $ MILLION)

FIGURE 12: GLOBAL CELL THERAPY MARKET, BY OTHERS, 2022-2030 (IN $ MILLION)

FIGURE 13: GLOBAL CELL THERAPY MARKET, BY NON-STEM CELL, 2022-2030 (IN $ MILLION)

FIGURE 14: GLOBAL CELL THERAPY MARKET, GROWTH POTENTIAL, BY THERAPY TYPE, IN 2021

FIGURE 15: GLOBAL CELL THERAPY MARKET, BY AUTOLOGOUS, 2022-2030 (IN $ MILLION)

FIGURE 16: GLOBAL CELL THERAPY MARKET, BY ALLOGENEIC, 2022-2030 (IN $ MILLION)

FIGURE 17: GLOBAL CELL THERAPY MARKET, GROWTH POTENTIAL, BY THERAPEUTIC APPLICATION, IN 2021

FIGURE 18: GLOBAL CELL THERAPY MARKET, BY MALIGNANCIES, 2022-2030 (IN $ MILLION)

FIGURE 19: GLOBAL CELL THERAPY MARKET, BY MUSCULOSKELETAL DISORDERS, 2022-2030 (IN $ MILLION)

FIGURE 20: GLOBAL CELL THERAPY MARKET, BY AUTOIMMUNE DISORDERS, 2022-2030 (IN $ MILLION)

FIGURE 21: GLOBAL CELL THERAPY MARKET, BY DERMATOLOGY, 2022-2030 (IN $ MILLION)

FIGURE 22: GLOBAL CELL THERAPY MARKET, BY OTHER APPLICATIONS, 2022-2030 (IN $ MILLION)

FIGURE 23: GLOBAL CELL THERAPY MARKET, GROWTH POTENTIAL, BY END-USER, IN 2021

FIGURE 24: GLOBAL CELL THERAPY MARKET, BY HOSPITALS & CLINICS, 2022-2030 (IN $ MILLION)

FIGURE 25: GLOBAL CELL THERAPY MARKET, BY ACADEMIC & RESEARCH INSTITUTES, 2022-2030 (IN $ MILLION)

FIGURE 26: NORTH AMERICA CELL THERAPY MARKET, COUNTRY OUTLOOK, 2021 & 2030 (IN %)

FIGURE 27: UNITED STATES CELL THERAPY MARKET, 2022-2030 (IN $ MILLION)

FIGURE 28: CANADA CELL THERAPY MARKET, 2022-2030 (IN $ MILLION)

FIGURE 29: EUROPE CELL THERAPY MARKET, COUNTRY OUTLOOK, 2021 & 2030 (IN %)

FIGURE 30: UNITED KINGDOM CELL THERAPY MARKET, 2022-2030 (IN $ MILLION)

FIGURE 31: GERMANY CELL THERAPY MARKET, 2022-2030 (IN $ MILLION)

FIGURE 32: FRANCE CELL THERAPY MARKET, 2022-2030 (IN $ MILLION)

FIGURE 33: ITALY CELL THERAPY MARKET, 2022-2030 (IN $ MILLION)

FIGURE 34: SPAIN CELL THERAPY MARKET, 2022-2030 (IN $ MILLION)

FIGURE 35: BELGIUM CELL THERAPY MARKET, 2022-2030 (IN $ MILLION)

FIGURE 36: POLAND CELL THERAPY MARKET, 2022-2030 (IN $ MILLION)

FIGURE 37: REST OF EUROPE CELL THERAPY MARKET, 2022-2030 (IN $ MILLION)

FIGURE 38: ASIA-PACIFIC CELL THERAPY MARKET, COUNTRY OUTLOOK, 2021 & 2030 (IN %)

FIGURE 39: CHINA CELL THERAPY MARKET, 2022-2030 (IN $ MILLION)

FIGURE 40: JAPAN CELL THERAPY MARKET, 2022-2030 (IN $ MILLION)

FIGURE 41: INDIA CELL THERAPY MARKET, 2022-2030 (IN $ MILLION)

FIGURE 42: SOUTH KOREA CELL THERAPY MARKET, 2022-2030 (IN $ MILLION)

FIGURE 43: THAILAND CELL THERAPY MARKET, 2022-2030 (IN $ MILLION)

FIGURE 44: SINGAPORE CELL THERAPY MARKET, 2022-2030 (IN $ MILLION)

FIGURE 45: AUSTRALIA & NEW ZEALAND CELL THERAPY MARKET, 2022-2030 (IN $ MILLION)

FIGURE 46: REST OF ASIA-PACIFIC CELL THERAPY MARKET, 2022-2030 (IN $ MILLION)

FIGURE 47: REST OF WORLD CELL THERAPY MARKET, REGIONAL OUTLOOK, 2021 & 2030 (IN %)

FIGURE 48: LATIN AMERICA CELL THERAPY MARKET, 2022-2030 (IN $ MILLION)

FIGURE 49: MIDDLE EAST & AFRICA CELL THERAPY MARKET, 2022-2030 (IN $ MILLION)

Segmentation

MARKET BY CELL TYPE
- STEM CELL
  - BONE MARROW
  - BLOOD
  - UMBILICAL CORD-DERIVED STEM CELL
  - ADIPOSE-DERIVED STEM CELL
  - OTHERS
- NON-STEM CELL
MARKET BY THERAPY TYPE
- AUTOLOGOUS
- ALLOGENEIC
MARKET BY THERAPEUTIC APPLICATION
- MALIGNANCIES
- MUSCULOSKELETAL DISORDERS
- AUTOIMMUNE DISORDERS
- DERMATOLOGY
- OTHER APPLICATIONS
MARKET BY END-USER
- HOSPITALS & CLINICS
- ACADEMIC & RESEARCH INSTITUTES
GEOGRAPHICAL ANALYSIS
- NORTH AMERICA
  - MARKET SIZE & ESTIMATES
  - KEY DRIVERS
  - KEY CHALLENGES
  - KEY PLAYERS
  - COUNTRY ANALYSIS
    - UNITED STATES
    - CANADA
- EUROPE
  - MARKET SIZE & ESTIMATES
  - KEY DRIVERS
  - KEY CHALLENGES
  - KEY PLAYERS
  - COUNTRY ANALYSIS
    - UNITED KINGDOM
    - GERMANY
    - FRANCE
    - ITALY
    - SPAIN
    - BELGIUM
    - POLAND
    - REST OF EUROPE
- ASIA-PACIFIC
  - MARKET SIZE & ESTIMATES
  - KEY DRIVERS
  - KEY CHALLENGES
  - KEY PLAYERS
  - COUNTRY ANALYSIS
    - CHINA
    - JAPAN
    - INDIA
    - SOUTH KOREA
    - THAILAND
    - SINGAPORE
    - AUSTRALIA & NEW ZEALAND
    - REST OF ASIA-PACIFIC
- REST OF WORLD
  - MARKET SIZE & ESTIMATES
  - KEY DRIVERS
  - KEY CHALLENGES
  - REGIONAL ANALYSIS
    - LATIN AMERICA
    - MIDDLE EAST & AFRICA

Request Free Sample

To request a free sample copy of this report, please complete the form below :

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

Frequently Asked Questions (FAQs):

What is the value of the global cell therapy market?

As of 2021, the global cell therapy market was valued at $2015.89 million.

Which is the fastest-growing cell type in the global cell therapy market?

Stem cell is the fastest-growing cell type in the global cell therapy market.

Which is the largest revenue-generating end-user in the global cell therapy market?

Academic & Research Institutes are the largest revenue-generating end-user in the global cell therapy market.

To request a free sample copy of this report, please complete the form below:

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

1-(857)293-0150